| Name | Title | Contact Details |
|---|
BioConvergence is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and approximately 13,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments.
Amlan International is the animal health business of Oil-Dri® Corporation of America, a leader in sorbent mineral technology. Amlan leverages Oil-Dri`s 80-plus years of mineral science expertise to develop proprietary, mineral-based feed additives that support optimal intestinal health while adding value for animal protein producers. The core of our feed additives is our natural mineral ingredient that contains high-capacity opal-CT lepispheres and undergoes proprietary thermal processing specifically tailored for each product. We also create synergistic blends of our mineral with other feed ingredients that further support normal gut function and digestive processes. Oil-Dri and the single-source mineral used in Amlan products are based in the USA, and because Amlan and Oil-Dri are vertically integrated, we control the quality, reliability, and safety of the mineral — from mine to feed bag. We do this by following sustainable mining practices and through the use of natural ingredients in our products. Our mineral-based feed additives meet the demands for cleaner food while reducing the inputs needed to raise production animals, helping to decrease the cost and environmental impact of poultry and livestock production. Leading integrators and producers worldwide trust our products to support animal intestinal health and add value to their operations. You can, too.
GenSight Biologics is is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. GenSight Biologics` pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics for retinitis pigmentosa, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. GenSight Biologics` lead product candidate, GS010, is in Phase III trials in Leber`s Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible low vision and legal blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics` product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Dova is a clinical-stage pharmaceutical company focused on acquiring, developing and commercializing drug candidates for rare diseases where there is a high unmet medical need. With a nimble approach and a team of bright minds aglow with passion, we’re...